Online inquiry

IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ666MR)

This product GTTS-WQ666MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD276 gene. The antibody can be applied in Cancers, brain, metastatic research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_001024736.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 80381
UniProt ID Q5ZPR3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ666MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13781MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-1033
GTTS-WQ151MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ4891MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BYM338
GTTS-WQ6453MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CT-P23
GTTS-WQ2041MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AHLX-20
GTTS-WQ4693MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986168
GTTS-WQ1738MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ADC-1013
GTTS-WQ15307MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA TNFR55-Ig1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW